Timothy A. McKinsey, Ph.D.
Associate
Professor
Associate
Division Head for Translational Research
Division
of Cardiology
University
of Colorado Denver
12700
E 19th Avenue, Room 8014A
Aurora
CO 80045
303-724-5476
(work)
303-464-7314
(home)
303-437-9553
(cell)
timothy.mckinsey@ucdenver.edu
Date and Place of Birth
March 18, 1968
Springfield, Missouri
Marital Status
Married with three children
Education
1986 - 1990: B.S., Biology,
University of Missouri,
Columbia
1993 - 1998: Ph.D.,
Microbiology and Immunology (with Dr. Dean Ballard), Vanderbilt
University, Nashville, TN;
Molecular Mechanisms of T Lymphocyte Activation
Experience and Honors
University
of Missouri
1990 -
1993: Research Associate (with Dr. Mark Hannink), Department of
Biochemistry, University of Missouri, Columbia;
Neoplastic Transformation by the c-Rel
Proto-Oncogene Product
Vanderbilt
University
1996:
Teaching Assistant, Vanderbilt
University Medical
Microbiology Course
1996
- 1997: Trainee, National Institutes of Health Program in Cellular,
Biochemical, and Molecular
Sciences
1997: Recipient, Sidney P. Colowick Award for Most
Outstanding Graduate Student, Department of Microbiology and Immunology,
Vanderbilt University School of Medicine
University of Texas Southwestern Medical Center
1998 - 8/2002: Postdoctoral
Fellow (with Dr. Eric Olson), Department
of Molecular Biology, University of Texas Southwestern Medical
Center at Dallas; Transcriptional
Control of Muscle Differentiation and Growth
1999
- 8/2002: Recipient, Pfizer Fellowship
from the Life Sciences Research Foundation
University of Colorado
8/2002 - present: Adjunct Assistant Professor, Department of Molecular,
Cellular, and Developmental
Biology, University of Colorado at Boulder
7/2003 - present: Adjunct Assistant
Professor, University of Colorado Cardiovascular Institute, Denver, Colorado
2002 - 2006: Lecturer,
Department of Molecular, Cellular, and Developmental Biology core course for
graduate students
2007 - 2009: Lecturer, MCDB
4201, Department of Molecular, Cellular, and Developmental Biology “From Bench
to Bedside” course for undergraduate students
Colorado
State University
2009: Lecturer, MGT450, College of Business “Biomedical Entrepreneurship”
course for graduate students
Myogen, Inc./Gilead Colorado, Inc.
8/2002 - 1/2004: Scientist I, Myogen, Inc., Westminster, CO
8/2002 – 8/2008: Project
Team Leader, Kinase Inhibitor for Heart
Failure, Myogen, Inc./Gilead Colorado, Inc. (Myogen acquired by Gilead Sciences
in 4Q 2006)
-guided project from target
discovery through lead optimization; project was a component of the Myogen/Novartis
collaboration
1/2004 - 1/2005: Scientist II, Myogen, Inc.
1/2004 – 12/2009: Group
Leader, In Vitro Biology, Gilead Colorado, Inc.
-recruited
and managed a team of 18 scientists (6 Ph.D., 12 B.S./M.S.) focused on small molecule drug discovery for
cardiovascular diseases
-responsibilities included:
target validation, lead discovery and optimization, pharmacodynamic marker
discovery and in vitro and ex vivo evaluation of in-licensing candidates
1/2005 - 07/2006: Project
Team Leader, Nuclear Enzyme Inhibitor
for Heart Failure, Myogen, Inc.;
-project
was component of the Myogen/Novartis collaboration
1/2005 - 1/2007: Scientist III, Myogen, Inc.
1/2007 - 1/2009: Senior Research Scientist II, Gilead Colorado, Inc.
1/2009 – 12/2009: Associate
Director, Biology, Gilead Colorado, Inc.
(Gilead Colorado closed 12/2009)
Publications
1. Diehl, J.A., McKinsey, T.A.,
and M. Hannink (1993) Differential pp40IkBb inhibition of DNA binding by rel proteins. Mol.
Cell. Biol. 13:1769-1778.
2. Sorkin, A., McKinsey, T. A.,
Shih, W., Kirchhausen, T., and G. Carpenter (1995) Stoichiometric interaction
of the epidermal growth factor receptor with the clatherin-associated protein
complex AP-2. J. Biol. Chem. 270:619-625.
3. Brockman, J.A., Scherer, D.C.,
McKinsey, T.A., Hall, S.M., Qi, X.,
Lee, W.Y., and D.W. Ballard (1995)
Coupling of a signal response domain in IkBa to multiple pathways for NF- kB activation. Mol. Cell. Biol. 15:2809-2818.
4. Rottjakob,
E.M., Sachdev, S., Leanna, C.A., McKinsey, T.A., and
M. Hannink (1996) PEST-dependent cytoplasmic retention of v-rel by IkBa:
evidence that IkBa regulates cellular localization of c-rel and v-rel by distinct mechanisms. J. Virol. 70:3176-3188.
5. McKinsey, T.A.,
Brockman, J.A., Scherer, D.C., Al-Murrani, S.W., Green, P.L., and D.W. Ballard
(1996) Inactivation of IkBb by the tax protein of human T-cell leukemia
virus: a potential mechanism for the
constitutive induction of NF-kB. Mol.
Cell. Biol. 16:2083-2090.
6. Chu, Z.L., McKinsey, T.A.,
Liu, L., Qi, X., and D.W. Ballard (1996) Basal phosphorylation of the PEST domain in IkBb regulates its functional interaction with
the c-rel proto-oncogene product. Mol.
Cell. Biol. 16:5974-5984.
7. Sachdev, S., Diehl, J.A., McKinsey,
T.A., Hans, A., and M. Hannink (1997) A threshold nuclear
level of the v-rel oncoprotein is required for transformation of avian
lymphocytes. Oncogene 14:2585-2594.
8. Chu, Z.L., McKinsey, T.A., Liu, L., Gentry, J.J., Malim, M.H., and D.W.
Ballard (1997) Suppression of tumor
necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kB control. Proc. Natl. Acad. Sci. U.S.A. 94:10057-10062.
9. McKinsey, T.A., Chu,
Z.L., and D.W. Ballard (1997) Phosphorylation of the PEST
domain of IkBb regulates the
function of NF-kB/IkBb complexes. J. Biol. Chem. 272:22377-22380.
10. Lu, J., McKinsey T.A.,
Xu, H., Wang, D-Z., Richardson,
J.A., and E.N. Olson (1999) FOG-2, a
cardiac and brain-enriched cofactor for GATA transcription factors. Mol. Cell.
Biol. 19: 4495-4502.
11. Meguro, T., Hong, J.C., Asai, K., Takagi, G., McKinsey, T.A., Olson, E.N., and S.F. Vatner (1999) Cyclosporine
attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and
heart failure. Circ. Res. 84:735-740.
12. McKinsey, T.A., and E.N. Olson (1999) Cardiac
hypertrophy: sorting out the circuitry. Curr.
Op. in Gen. & Dev. 9:267–274.
13. Jo, H., Zhang, R., Zhang, H., McKinsey,
T.A., Shao, J., Beauchamp, R.D., Ballard, D.W., and P. Liang (2000) NF-kB is required for H-ras oncogene induced
abnormal cell tumorigenesis. Oncogene 19:841-849.
14. Lu, J., McKinsey, T.A.,
Nicol, R.L., and E.N. Olson (2000) Signal-dependent activation of the myocyte
enhancer factor-2 transcription factor by dissociation from histone
deacetylases. Proc. Natl. Acad. Sci. U. S. A. 97:4070-4075.
15. Wu, H., Naya, F.J., McKinsey,
T.A., Mercer, B., Shelton, J.M., Chin, E.R., Simard, A.R., Michel, R.N., Bassel-Duby, R.,
Olson, E.N., and R.S. Williams (2000) MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle
fiber type. EMBO J. 19:1963-1973.
16. Passier, R., Zeng, H., Frey, N., Naya, F.J., Nicol, R.L., McKinsey, T.A., Overbeek, P., Richardson, J.A., Grant, S.R., and E.N.
Olson (2000) CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:1395-1406.
17. Lu, J., McKinsey, T.A., (co-first authors),
Zhang, C.L., and E.N. Olson (2000) Regulation
of skeletal myogenesis by
association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell. 6:233-244.
18. Frey, N., McKinsey, T.A.,
and E.N. Olson (2000) Decoding calcium signals involved in cardiac growth and
function. Nat. Med. 6:1221-1227.
19. McKinsey, T.A., Zhang,
C.L., Lu, J., and E.N. Olson (2000) Signal-dependent nuclear export of a
histone deacetylase regulates muscle differentiation. Nature 408:106-111.
20. Yang, J., Rothermel, B., Vega, R.B., Frey, N., McKinsey, T.A., Olson, E.N.,
Bassel-Duby, R., and R.S. Williams (2000) Independent signals control
expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated
muscles. Circ. Res. 87:E61-68.
21. McKinsey, T.A.,
Zhang, C.L., (co-first authors) and E.N. Olson
(2000) Activation of the myocyte
enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein
kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl.
Acad. Sci. U. S. A. 97:14400 -
14405.
22. Zhang, C.L., McKinsey, T.A.,
Lu, J.R., and E.N. Olson (2001) Association of COOH- terminal-binding protein (CtBP) and MEF2-interacting
transcription repressor (MITR) contributes
to transcriptional repression of the MEF2 transcription factor. J. Biol.
Chem. 276:35-39.
23. Rothermel, B.A., McKinsey,
T.A., Vega, R.B., Nicol, R.L., Mammen, P., Yang, J., Antos, C.L., Shelton,
J.M., Bassel-Duby, R., Olson, E.N., and R.S. Williams (2001) Myocyte-enriched
calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.
Proc. Natl. Acad. Sci. U. S. A. 98:3328-3333.
24. McKinsey, T.A., Chu,
Z.L., and D.W. Ballard (2001) Transcription factor NF-kB regulates inducible CD83 gene expression in activated T
lymphocytes. Mol. Immunol. 37:783-788.
25. Zhang, C.L., McKinsey, T.A., and E.N. Olson (2001) The
transcriptional co-repressor MITR is a signal-responsive inhibitor of skeletal
myogenesis. Proc. Natl. Acad. Sci. U.
S. A. 98:7354-7359.
26. McKinsey, T.A., Zhang,
C.L., and E.N. Olson (2001) Control of muscle development by dueling HATs and
HDACs. Curr. Op. in Gen. & Dev.
11:497-504.
27. McKinsey, T.A., Zhang,
C.L., and E.N. Olson (2001) Identification of a signal-responsive nuclear export sequence in class II
histone deacetylases. Mol. Cell.
Biol. 21: 6312-6321.
28. McKinsey, T.A., Zhang,
C.L., and E.N. Olson (2002) The MEF2 transcription factor: a calcium-dependent regulator of cell
division, differentiation, and growth. TiBS.
27: 40-47.
29. Antos, C.L., McKinsey, T.A.,
Frey, N., Kutschke, W., McAnally, J., Shelton, J.M., Richardson, J.A., Hill,
J.A., and E.N. Olson (2002) Activated glycogen synthase kinase-3b suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S.
A. 99:907-912.
30. Zhang, C.L., McKinsey,
T.A., Chang, S. Antos, C.L., Hill, J.A., and E.N. Olson (2002) Class II
histone deacetylases act as signal-responsive repressors of cardiac
hypertrophy. Cell 110: 479-488.
31. Zhang, C.L., McKinsey,
T.A., and E.N. Olson (2002) Association of class II histone deacetylases
with heterochromatin protein 1: potential role for histone methylation in
control of muscle differentiation. Mol. Cell. Biol. 22:
7302-7312.
32. McKinsey, T.A.,
Zhang, C.L., and E.N. Olson (2002) Signaling chromatin to make muscle. Curr. Op. in Cell Biol. 14:763-772.
33. Antos, C.L., McKinsey,
T.A., (co-first authors),
Dreitz, M., Hollingsworth, L.M., Zhang, C.L., Schreiber, K., Rindt, H.,
Gorczynski, R.J., and E.N. Olson (2003)
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase
inhibitors. J. Biol. Chem.
278:28930-28937.
34. Bush, E., Fielitz, J.,
Melvin, L., Martinez-Arnold, M., McKinsey, T.A., Plichta, R., and E.N.
Olson (2004) A small molecular
activator of cardiac hypertrophy uncovered in a chemical screen for modifiers
of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U S A. 101:2870-2875.
35. McKinsey, T.A. and E.N. Olson (2004) Cardiac histone
acetylation: therapeutic opportunities abound.
TiGS 20:206-213.
36. McKinsey, T.A., and
E.N. Olson (2004) Dual roles of histone deacetylases in the
control of cardiac growth. Novartis Found. Symp. 259:132-141.
37. Vega, R.B., Harrison,
B.C., Meadows, E., Roberts, C.R., Papst, P.J., Olson, E.N., and T.A.
McKinsey (2004) Protein
kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear
export of histone deacetylase 5. Mol. Cell Biol. 24:8374-8385.
38. Chang, S., McKinsey, T.A. (co-first authors), Zhang, C.L., Richardson, J.A., Hill, J., and E.N. Olson
(2004) Histone deacetylases 5 and 9 govern responsiveness of the heart
to a subset of stress signals and play redundant roles in heart development. Mol.
Cell Biol.
24:8467-8476.
39. Harrison,
B.C., Roberts, C.R., Hood, D.B., Sweeney, M., Gould, J.M., Bush, E.W., and T.A.
McKinsey (2004) The CRM1 nuclear
export receptor controls pathological cardiac gene expression. Mol Cell Biol. 24:10636-10649.
40. McKinsey, T.A., and
E.N. Olson (2005) Toward transcriptional therapies for the failing heart:
chemical screens to modulate genes. J.
Clin. Invest. 115:538-546.
41. Parra, M., Kasler, H., McKinsey,
T.A., Olson, E.N., and E. Verdin (2005) Protein kinase D1 phosphorylates HDAC7 and Induces its nuclear export
after TCR activation. J. Biol. Chem. 280:13762-13762.
42. McKinsey, T.A., and E.N. Olson (2005) Regulation of muscle
gene expression by histone deacetylases. In: Histone deacetylases:
Transcriptional regulation and other functions; Humana Press Inc.
43. McKinsey, T.A., Kuwahara,
K., Bezprozvannaya, S., and E.N. Olson (2006)
Class II histone deacetylases confer signal responsiveness to the
ankyrin-repeat proteins ANKRA2 and RFXANK.
Mol. Biol. Cell. 17:438-447.
44. Matthews, S.A., Liu, P., Spitaler, M., Olson, E.N., McKinsey, T.A., Cantrell, D.A., and
A.M. Scharenberg (2006) Essential role for protein kinase D family kinases in
the regulation of class II histone deacetylases in B lymphocytes. Mol.
Cell. Biol. 26:1569-1577.
45. Wu, X., Zhang, T., Bossuyt, J., Li, X., McKinsey, T.A., Dedman, J.R., Olson, E.N., Chen, J., Brown, J.H., and
D.M. Bers (2006) Local InsP3-dependent perinuclear Ca2+ signaling in
cardiac myocyte excitation-transcription coupling. J.
Clin. Invest. 116:675-682.
46. Huynh, Q.K., and T.A.
McKinsey (2006) Protein kinase D directly phosphorylates histone deacetylase
5 via a random sequential kinetic mechanism. Arch. Biochem. Biophys. 450:141-148.
47. Harrison, B.C., Kim, M.S., van Rooij, E., Plato, C.F., Papst, P.J.,
Vega, R.B., McAnally, J.A., Richardson, J.A., Bassel-Duby, R., Olson, E.N., and
T.A. McKinsey (2006) Regulation of
cardiac stress signaling by protein kinase D1. Mol. Cell. Biol. 26:3875-3888.
48. Bush, E.W., Hood, D.B., Papst, P.J., Chapo, J.A., Minobe, W.,
Bristow, M.R., Olson, E.N., and T.A.
McKinsey (2006) Canonical transient receptor potential channels promote
cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 281:33487-33496.
49. Olson, E.N., Backs, J., and T.A.
McKinsey (2006) Control of cardiac hypertrophy and heart failure by histone
acetylation/deacetylation. Novartis
Found. Symp. 274:3-12;
discussion 13-9, 152-5, 272-276.
50. McKinsey, T.A. (2007)
Derepression of pathological cardiac genes by members of the CaM
kinase superfamily. Cardiovasc Res. 73:667-677.
51. McKinsey, T.A., and D.A.
Kass (2007) Small molecule therapies for cardiac hypertrophy: moving beneath
the cell surface. Nat. Rev. Drug Discov.
6:617-635.
52. Xu, X., Ha, C.H., Wong, C.,
Wang, W., Hausser, A., Pfizenmaier, K., Olson, E.N., McKinsey, T.A., and Z.G. Jin (2007) Angiotensin II stimulates
protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear
export leading to vascular smooth muscle cell hypertrophy. Arterioscler. Thromb. Vasc. Biol. 27:2355-2362.
53. Renthal, W., Maze, I.,
Krishnan, V., Covington, H.E., Xiao, G., Kumar, A., Russo, S.J., Graham, A.,
Tsankova, N., Kippin, T.E., Kerstetter, K.A., Neve, R.L., Haggarty, S.J., McKinsey, T.A., Bassel-Duby, R., Olson,
E.N., and E.J. Nestler (2007) Histone deacetylase 5 epigenetically controls
behavioral adaptations to chronic emotional stimuli. Neuron 56:517-529.
54. Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T.A., and E.N. Olson (2008)
Histone
deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by
oligomerization with histone deacetylase 4. Mol.
Cell. Biol. 28:3437-3445.
55. Ha, C.H., Wang, W., Jhun, B.S., Wong, C.,
Hausser, A., Pfizenmaier, K., McKinsey,
T.A., Olson, E.N., and Z.G. Jin (2008) Protein kinase D-dependent phosphorylation
and nuclear export of histone deacetylase 5 mediates vascular endothelial
growth factor-induced gene expression and angiogenesis. J.
Biol. Chem. 283:14590-14599.
56. Kim, M.S., Fielitz, J., McAnally, J., Shelton, J.M., Lemon, D.D., McKinsey, T.A., Richardson,
J.A., Bassel-Duby, R., and E.N. Olson (2008) Protein kinase D1 stimulates MEF2
activity in skeletal muscle and enhances muscle performance. Mol. Cell. Biol. 28:3600-3609.
57. YY1 protects cardiac myocytes from pathologic
hypertrophy by interacting with HDAC5.
Sucharov, C.C.,
Dockstader, K. and T.A. McKinsey
(2008) Mol. Biol. Cell. 19:4141-4153.
58. Suppression of
HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors
of CRM1. Monovich, L., Koch, K.A., Burgis, R., Osimboni, E., Mann, T., Wall, D.,
Gao, J., Feng, Y., Vega, R.B., Turner, B.A., Hood, D.B., Law, A., Papst, P.J., Koditek,
D., Chapo, J.A., Reid, B.G., Melvin, L.S., Pagratis, N.C. and T.A. McKinsey (2009) Biochim. Biophys. Acta. 1789:422-431.
59. Targeting histone deacetylases for heart
failure. Bush, E.W. and T.A. McKinsey (2009) Expert Opin. Ther. Targets 13:767-784.
60. Increased phosphorylation-dependent
nuclear export of class II histone deacetylases in failing human heart. Calalb, M.B., McKinsey, T.A., Newkirk, S., Huynh, K., C.C., Sucharov, C.C. and
M.R. Bristow (2009) Clinical and
Translational Science 2: 325-332.
61. Protein acetylation in the cardiorenal axis:
the promise of histone deacetylase inhibitors.
Bush, E.W. and T.A. McKinsey
(2010) Circulation Research 106:272-284.
62.
A novel kinase inhibitor establishes a
predominant role for protein kinase D as a cardiac class IIa histone
deacetylase kinase. Monovich, L., Vega,
R.B., Meredith, E., Miranda, K., Rao, C., Capparelli, M., Lemon, D.D., Phan,
D., Koch, K.A., Chapo, J.A., Hood, D.B., and T.A. McKinsey (2010) FEBS
Lett. 584:631-637.
63. Protein kinase C-related kinase
targets nuclear localization signals in a subset of class IIa histone
deacetylases. Harrison, B.C., Huynh, K., Lundgaard, G.L., Helmke, S.M.,
Perryman, M.B., and T.A. McKinsey
(2010) FEBS Lett. 584:1103-1110.
64.
Identification
of Orally Available Naphthyridine Protein Kinase D Inhibitors. Meredith,
E.L., Ardayfio, O, Beattie, K., Dobler,M.R., Enyedy, I., Gaul, C., Hosagrahara,
V., Jewell, C., Koch, K., Lee, W.,
Lehmann, H., McKinsey, T.A.,
Miranda, K., Pagratis, N., Pancost, M., Patnaik, A., Phan, D., Plato, C., Qian,
M., Rajaraman, V., Rao, C., Rozhitskaya, O., Ruppen, T., Shi, J., Siska, S.J.,
Springer, C., van Eis, M., Vega, R.B., vonMatt, A., Yang, L., Yoon, T., Zhang,
J-H.,Zhu, N., and L.G. Monovich (2010) Journal
of Med. Chem. In Press.
65. Potent and selective thyromimetics lacking
structural similarity to thyroid hormone regulate cardiac myosin heavy chain expression. Bush, E.W., McQuire, L., Gamber, G.G.,
Ksander, G., Jain, R.K., Sung, M.J., Tallarico, J.A., Tomassi, Vega, R.B.,
Shetty, S., Plato, C., Pitts, K., Chapo, J., Schreiber, K., Kronlage, J., McKinsey, T.A., Castonguay, L.A., Pagratis,
N., Todd, J., Glascock, C., Peng, Y., Gorczynski, R.J., and L.S. Melvin (2009) Submitted.
66. Preliminary studies of 3,5-diarylazoles as
novel and selective inhibitors of protein kinase D. Gamber, G., Meredith, E., Zhu, Q., Yan, W.,
Rao, C., Capparelli, M., Burgess, R., Enyedy, I., Zhang, J.H., Soldermann, N.,
Koch, K., Pagratis, N., Hosagrahara, V., Vega, R.B., McKinsey, T.A., and Lauren Monovich (2009) Submitted.
Patents
1.
Olson, E.N., Lu, J.R., and T.A. McKinsey
(2001) Methods and compositions relating to histone deacetylase 4 and 5
regulation of cardiac gene expression.
United States Patent No. 6,632,628.
2. Bristow, M.R., Long, C., McKinsey, T.A. and E.N. Olson (2003)
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy. United States Patent No. 6,706,686.
3. McKinsey, T.A., Olson, E.N., and R.B. Vega (2004) Inhibition of
protein kinase C-m (protein kinase D; PKD) as a treatment
for cardiac hypertrophy and heart failure. WO
2004112763.
4. McKinsey, T.A., Olson, E.N., Harrison, B.C., Rybkin, I., and S.
Helmke (2005) Inhibition of protein kinase C-related kinase (PRK) as a
treatment for cardiac hypertrophy and heart failure. WO 2005074941.
5. Bush, E.W., Gorczynski, R.J.,
Koch, K., and McKinsey, T.A. (2007) Use
of inhibitors of the ubiquitin proteasome pathway as a method of increasing
contractility of the heart. US
2007015777
6. T.A. McKinsey (2005) Inhibition of nuclear export as a treatment
for cardiac hypertrophy and heart failure. WO
2005097088.
7. Backs,
J., Harrison, B.C., Huynh, K., McKinsey, T.A., Olson, E.N., and N.
Pagratis
(2007) Methods of treatment and
uses for CaMKII and its interaction with HDACs and calpain. WO 2007059533.
Editorial Boards
Current Drug Discovery Technologies
Recent Patents on Cardiovascular Drug Discovery
Invited Speaker
2000: Department of
Microbiology and Immunology/Interdisciplinary Graduate Program, Vanderbilt University
Medical Center,
Nashville, TN
2001: Department of
Cellular and Molecular Physiology, Pennsylvania State College of Medicine,
Hershey, PA
2001: Gordon Conference on Myogenesis, Il Ciocco, Italy
2001: Gordon Conference on
Calcium Signaling, Oxford, England
2001: 5th Annual
Meeting of the Heart Failure Society of America,
Washington, D.C.
2002: 24th
Annual Meeting of the International Society for Heart Research, Madison, WI
2002: 6th Annual Meeting of the Heart Failure
Society of America, Boca Raton, FL
2002:
American Heart Association (AHA)
Scientific Sessions, Chicago,
IL
2003: Department of Pharmacology, University of Colorado Health
Sciences Center,
Denver
2003: Annual Experimental Biology Meeting, San Diego, CA
2003: Second Annual Symposium of the
GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease,
Philadelphia, PA
2004: 8th Annual Meeting of the
Heart Failure Society of America,
Toronto
2005: University of Missouri
Symposium on Science in Industry
2006: 3rd Annual AHA Symposium
on Basic Cardiovascular Sciences, Keystone, CO
2006: 10th Annual Meeting of the
Heart Failure Society of America,
Seattle
2006: University
of South Dakota School of Medicine
2007: World Congress of the
International Society for Heart Research, Bologna,
Italy
2007: Keystone Symposium on
Histone Deacetylases, Snowmass,
CO
2007: Ohio St. University
Program in Molecular, Cellular and Developmental Biology, Columbus, Ohio
2008: University of Colorado
Health Sciences Center Alternative Careers in Science
seminar series
2009: Colorado State
University Department of Cell and Molecular Biology
2009: University of Florida Center for Epigenetics
Research Support
1R43HL74544-01A1 – 01/04
– 01/05*
NIH/NHLBI - $100,000
Phase I SBIR
Development
of Kinase Inhibitors to Treat Cardiac Hypertrophy and Heart Failure
*Funds returned to NIH following signing
of collaborative agreement between Myogen and Novartis